Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
961 to 980 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of diagnostic genes and vital microRNAs involved in rheumatoid arthritis: based on data mining and experimental verification. | PeerJ | 2021 | 34040897 | PubTator, text mining | PubMed |
| Phenotypic plasticity underlies local invasion and distant metastasis in colon cancer. | Elife | 2021 | 34036938 | PubTator, text mining | PubMed |
| Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses. | J Transl Med | 2021 | 34030694 | PubTator, text mining | PubMed |
| Modeling the Th17 and Tregs Paradigm: Implications for Cancer Immunotherapy. | Front Cell Dev Biol | 2021 | 34026764 | PubTator, text mining | PubMed |
| Network-based analysis of key regulatory genes implicated in Type 2 Diabetes Mellitus and Recurrent Miscarriages in Turner Syndrome. | Sci Rep | 2021 | 34021221 | PubTator, text mining | PubMed |
| Ovalbumin Antigen-Specific Activation of Human T Cell Receptor Closely Resembles Soluble Antibody Stimulation as Revealed by BOOST Phosphotyrosine Proteomics. | J Proteome Res | 2021 | 34018748 | PubTator, text mining | PubMed |
| Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection. | Heliyon | 2021 | 34013078 | PubTator, text mining | PubMed |
| Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy. | Front Immunol | 2021 | 34012443 | PubTator, text mining | PubMed |
| Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge. | Clin Exp Immunol | 2021 | 34008169 | PubTator, text mining | PubMed |
| Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma. | Bioorg Chem | 2021 | 34000704 | PubTator, text mining | PubMed |
| Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia. | Front Oncol | 2021 | 33996605 | PubTator, text mining | PubMed |
| Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. | Front Oncol | 2021 | 33996600 | PubTator, text mining | PubMed |
| Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations. | Chem Sci | 2021 | 33995994 | PubTator, text mining | PubMed |
| Case Report: Primary Immunodeficiencies, Massive EBV+ T-Cell Lympoproliferation Leading to the Diagnosis of ICF2 Syndrome. | Front Immunol | 2021 | 33995370 | PubTator, text mining | PubMed |
| SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. | Front Pharmacol | 2021 | 33986687 | PubTator, text mining | PubMed |
| WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma. | Cancer Med | 2021 | 33982398 | PubTator, text mining | PubMed |
| Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. | Mol Ther Oncolytics | 2021 | 33981831 | PubTator, text mining | PubMed |
| Post-Translational Modifications in Transcription Factors that Determine T Helper Cell Differentiation. | Mol Cells | 2021 | 33972470 | PubTator, text mining | PubMed |
| CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment. | Front Immunol | 2021 | 33968066 | PubTator, text mining | PubMed |
| Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. | Cell | 2021 | 33961781 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=49